Gross impairment of hepatic drug metabolism in a patient with chronic liver disease.
作者信息
Adjepon-Yamoah K K, Nimmo J, Prescott L F
出版信息
Br Med J. 1974 Nov 16;4(5941):387-8. doi: 10.1136/bmj.4.5941.387.
Abstract
摘要
相似文献
1
Gross impairment of hepatic drug metabolism in a patient with chronic liver disease.慢性肝病患者肝脏药物代谢严重受损。
Br Med J. 1974 Nov 16;4(5941):387-8. doi: 10.1136/bmj.4.5941.387.
2
Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease.慢性肝病中安替比林、对乙酰氨基酚和利多卡因的消除情况。
Br Med J. 1977 May 28;1(6073):1384-7. doi: 10.1136/bmj.1.6073.1384.
3
Antipyrine and lidocaine are cleared faster in horses than in humans: acetaminophen may be handled similarly.安替比林和利多卡因在马体内的清除速度比在人体内更快：对乙酰氨基酚的代谢情况可能类似。
Pharmacology. 1987;34(4):192-200. doi: 10.1159/000138269.
4
Drug metabolism in liver disease. Identification of patients with impaired hepatic drug metabolism.
Gastroenterology. 1978 Oct;75(4):580-8.
5
[Drug metabolism in patients with liver disease (author's transl)].肝病患者的药物代谢（作者译）
Leber Magen Darm. 1980 Oct;10(5):234-40.
6
Drug disposition in patients with HBsAg-positive chronic liver disease.
Dig Dis Sci. 1987 Jul;32(7):710-4. doi: 10.1007/BF01296136.
7
[Changes in metabolic function of the liver in patients with chronic hepatic diseases].[慢性肝病患者肝脏代谢功能的变化]
Bratisl Lek Listy. 1985 Jan;83(1):35-40.
8
9
Altered elimination of antipyrine in patients with acute viral hepatitis.急性病毒性肝炎患者安替比林消除情况的改变。
Gut. 1976 May;17(5):341-4. doi: 10.1136/gut.17.5.341.
10
The effect of chlorpromazine on drug metabolism.
J Pharm Pharmacol. 1972 Jul;24(7):577-8. doi: 10.1111/j.2042-7158.1972.tb09060.x.
引用本文的文献
1
Assessment of liver metabolic function. Clinical implications.肝脏代谢功能评估。临床意义。
Clin Pharmacokinet. 1994 Sep;27(3):216-48. doi: 10.2165/00003088-199427030-00005.
2
Disposition of antipyrine in patients with extensive metastatic liver disease.安替比林在广泛转移性肝病患者中的处置情况。
Eur J Clin Pharmacol. 1992;42(5):465-9. doi: 10.1007/BF00314851.
3
Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure.心肌梗死和心力衰竭患者利多卡因代谢受损。
Br Med J. 1976 Apr 17;1(6015):939-41. doi: 10.1136/bmj.1.6015.939.
4
Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease.慢性肝病中安替比林、对乙酰氨基酚和利多卡因的消除情况。
Br Med J. 1977 May 28;1(6073):1384-7. doi: 10.1136/bmj.1.6073.1384.
5
Drug metabolism in liver disease.肝脏疾病中的药物代谢
J Clin Pathol Suppl (R Coll Pathol). 1975;9:62-5.
6
Drug kinetics and hepatic blood flow.药物动力学与肝血流量
Clin Pharmacokinet. 1979 Nov-Dec;4(6):433-48. doi: 10.2165/00003088-197904060-00003.
7
Clinical pharmacokinetics of lignocaine.利多卡因的临床药代动力学。
Clin Pharmacokinet. 1978 May-Jun;3(3):177-201. doi: 10.2165/00003088-197803030-00001.
8
Tropical cirrhosis and hepatoma.热带性肝硬化与肝癌
J R Coll Physicians Lond. 1976 Jan;10(2):133-44.
本文引用的文献
1
2
The influence of heart failure, liver disease, and renal failure on the disposition of lidocaine in man.心力衰竭、肝脏疾病和肾衰竭对利多卡因在人体内处置的影响。
Am Heart J. 1971 Sep;82(3):417-21. doi: 10.1016/0002-8703(71)90308-5.
3
Determinants of serum antipyrine half-lives in patients with liver disease.肝病患者血清安替比林半衰期的决定因素。
Gut. 1973 Jul;14(7):569-73. doi: 10.1136/gut.14.7.569.
4
Rapid gas-liquid chromatographic estimation of antipyrine in plasma.血浆中安替比林的快速气-液色谱法测定
J Pharm Pharmacol. 1973 Mar;25(3):205-7. doi: 10.1111/j.2042-7158.1973.tb10625.x.
Zotero 插件